Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provenge, Jevtana Covered Without PA By Nearly 50% Of Payers In Analysis

Executive Summary

Dendreon’s Provenge (sipuleucel-T) and Sanofi-Aventis’ Jevtana (cabazitaxel) were covered by nearly 50% of commercial plans without prior authorization requirements during the first quarter of 2011, according to an analysis of payer policies for the novel prostate cancer therapies conducted by The Zitter Group.

You may also be interested in...



NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis

The U.K.'s cost regulator, NICE, rejects Sanofi's lauded prostate cancer therapy cabazitaxel because it considers it too expensive.

Medicare Provenge Decision Addresses Treatment Eligibility Criteria

The final national coverage decision confirms that Provenge will be covered for its labeled uses and that off-label use will be left to the discretion of local administrative claims contractors.

Provenge Medicare NCD Needs More Clarity To Avoid Restrictions, CMS Told

Medicare’s final national coverage decision on Dendreon’s prostate cancer vaccine Provenge (sipuleucel-T) should more clearly lay out how far local Medicare claims contractors can go in ensuring patients are eligible for treatment, comments from the manufacturer, oncology care providers and physicians say.

Related Content

Topics

UsernamePublicRestriction

Register

PS053467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel